Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
ONL Therapeutics revenue
ONL Therapeutics's revenue is $150,000.
What is ONL Therapeutics's revenue?
- ONL Therapeutics has 28 employees, and the revenue per employee ratio is $5,357.
- ONL Therapeutics peak revenue was $150.0K in 2024.
On this page
Zippi applies for you, and finds you a job.
ONL Therapeutics financing
ONL Therapeutics received early financing of $501.8K on 2014-07-02.
| Series | Round size | Date |
|---|---|---|
| Seed | $502K | 07/2014 |
| Grant | $1.4M | 11/2014 |
| Debt Financing | $916K | 08/2016 |
| Grant | $1M | 03/2017 |
| Series A | $4.3M | 05/2017 |
| Convertible Note | $3M | 08/2019 |
| Series B | $46.9M | 12/2020 |
ONL Therapeutics investors
| Investors | Security type |
|---|---|
| Capital Community Angel Investors | Seed |
| National Institutes of Health (NIH) | Grant |
| Novartis | Series A |
| ExSight Ventures | Series A |
| Capital Community Angel Investors | Series A |
| Biosciences Research and Commercialization Center (BRCC) | Series A |
| Hestia Investments | Series A |
| MINTS | Series A |
| InvestMichigan | Series A |
| Capital Community Angel Investors | Convertible Note |
| InFocus Capital Partners LLC | Convertible Note |
| Invest Michigan | Convertible Note |
| Johnson & Johnson Innovation – JJDC | Series B |
| PSQ Capital | Series B |
| Grand Angels | Series B |
| Bios Partners | Series B |
| ExSight Ventures | Series B |
| Capital Community Angel Investors | Series B |
| Biosciences Research and Commercialization Center (BRCC) | Series B |
| MINTS | Series B |
| InFocus Capital Partners LLC | Series B |
| Kaitai Capital | Series B |
Search for jobs
Most in demand jobs
Zippia gives an in-depth look into the details of ONL Therapeutics, including salaries, political affiliations, employee data, and more, in order to inform job seekers about ONL Therapeutics. The employee data is based on information from people who have self-reported their past or current employments at ONL Therapeutics. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by ONL Therapeutics. The data presented on this page does not represent the view of ONL Therapeutics and its employees or that of Zippia.
ONL Therapeutics may also be known as or be related to ONL Therapeutics, ONL Therapeutics Inc and ONL Therapeutics, Inc.